Early results from an experimental coronavirus vaccine show no major safety problems and suggest that it spurs the desired immune system responses, researchers reported on Wednesday in the New England Journal of Medicine.
The US government has awarded Novavax, a company based in Gaithersburg, Maryland, USD 1.6 billion to help develop and make the vaccine, which is given as two shots, three weeks apart. It includes a protein from the coronavirus to prompt the immune system to make antibodies to fight infection.
The study tested two dose levels in 108 healthy people and compared responses to 23 others who got placebo shots. Most of those given vaccine also received an adjuvant — a substance often included in vaccines to boost the immune system’s response and stretch a limited supply.
The adjuvant seemed safe; those who got it with the lower dose made antibodies in far greater numbers than what’s typically seen in people recovering from natural infection with COVID-19, researchers reported.
The work was sponsored by the Coalition for Epidemic Preparedness Innovations, a nonprofit focused on increasing vaccine availability worldwide.
Three other experimental vaccines are in late-stage testing in the United States.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
